The Independent on MSN4mon
Donanemab patient: ‘The drug kept me feeling normal, but i’m scared about what happens next’
Peter Almond finished a trial for Donanemab in September having been on the drug for three years. Donanemab is one of the new ...
pharmaphorum6mon
Lilly ramps up Irish manufacturing investment by $1bn
Production of biologic active ingredients at the site is scheduled to start in 2026. Part of the Limerick site's production capacity has been earmarked for donanemab, which was approved by the US ...
News Medical26d
Lecanemab and donanemab slow Alzheimer’s decline, but is the benefit worth the cost?
New research shows that lecanemab and donanemab can slow cognitive decline and extend patients' independence in daily activities. But with high costs and risks, are these treatments truly ...